3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
34
Specimen Handling
18
Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
Biopsy
14
Nivolumab
13
Ipilimumab
12
Gemcitabine
10
Irinotecan
9
Radiosurgery
8
atezolizumab
7
abemaciclib
7
Radiation
7
Pemetrexed
7
Cisplatin
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
trastuzumab deruxtecan
6
olaparib
6
durvalumab
6
avelumab
6
Docetaxel
6
osimertinib
5
adagrasib
5
Trastuzumab
5
Fulvestrant
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm Metastasis
×
AZD9833
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04214288
2025-11-20
SERENA-2
AstraZeneca
Phase 2
Active not recruiting
240 enrolled
16 charts
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled